Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 0.71 |
| ▸ | AKT1 | P31749 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.64 |
| ▸ | PPARG | P37231 | 2/20 | 0.64 |
| ▸ | PPARA | Q07869 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30461429 | 1.00 | ALOX5 (0.71) | ALOX5AKT1NR1I2PPARGPPARA | |
| SCHEMBL19660125 | 0.90 | ALOX5 (0.65) | ALOX5AKT1NR1I2PPARGPPARA | |
| SCHEMBL3270839 | 0.82 | AKT1 (0.65) | ALOX5AKT1NR1I2PPARGPPARA | |
| SCHEMBL407517 | 0.82 | AKT1 (0.65) | ALOX5AKT1NR1I2PPARGPPARA | |
| SCHEMBL5441388 | 0.82 | AKT1 (0.65) | ALOX5AKT1NR1I2PPARGPPARA | |
| SCHEMBL29393858 | 0.82 | AKT1 (0.65) | ALOX5AKT1NR1I2PPARGPPARA | |
| SCHEMBL20819457 | 0.81 | AKT1 (0.66) | ALOX5AKT1NR1I2PPARGPPARA | |
| SCHEMBL6027762 | 0.81 | AKT1 (0.66) | ALOX5AKT1NR1I2PPARGPPARA | |
| SCHEMBL4643458 | 0.79 | ALOX5 (0.66) | ALOX5NR1I2PPARGPPARA | |
| SCHEMBL15441680 | 0.79 | AKT1 (1.00) | ALOX5AKT1NR1I2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | claimed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | claimed |
| US-7119117-B2 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | GALILEO PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | claimed |
| US-7081476-B2 | Tocopherol enriched compositions for reducing IL6 levels | GALILEO PHARMACEUTICALS, INC. (US) | 2006-07-25 | — | — | US | claimed |
| US-20050124689-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | CHENANGO ZERO LLC | 2005-06-09 | — | — | US | claimed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | claimed |
| JP-57145871-A | — | — | None | — | — | JP | disclosed |
| US-20170296505-A1 | LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9676744-B2 | Long-chain carboxychromanols and analogs for use as anti-inflammatory agents | PURDUE RESEARCH FOUNDATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-8822529-B2 | Long-chain carboxychromanols and analogs for use as anti-inflammatory agents | PURDUE RESEARCH FOUNDATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-20050112078-A1 | Plant-derived protein extract compositions and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1418904-A2 | TOCOPHEROL ENRICHED COMPOSITIONS AND AMELIORATION OF INFLAMMATORY SYMPTOMS | Galileo Laboratories, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030100603-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | JOHNSON & JOHNSON CONSUMER INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003015494-A2 | TOCOPHEROL ENRICHED COMPOSITIONS AND AMELIORATION OF INFLAMMATORY SYMPTOMS | GALILEO PHARMACEUTICALS, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| JP-S57145871-A | CHROMANOLCARBOXYLIC DERIVATIVE | EISAI CO LTD | 1982-09-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124689-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | TTPA, TNNT2, GSR | ALOX5 35/4885AKT1 4522/4885NR1I2 823/4885 |
| US-20170296505-A1 | LONG-CHAIN CARBOXYCHROMANOLS AND ANALOGS FOR USE AS ANTI-INFLAMMATORY AGENTS | ALOX12, ALOX5, PTGS1 | ALOX5 2/4885AKT1 3134/4885NR1I2 997/4885 |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | ALOX5 1992/4885AKT1 3301/4885NR1I2 2593/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALOX5 1604/4885AKT1 3502/4885NR1I2 2663/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALOX5 1604/4885AKT1 3502/4885NR1I2 2663/4885 |
| US-20030100603-A1 | Tocopherol enriched compositions and amelioration of inflammatory symptoms | TTPA, TNNT2, GSR | ALOX5 35/4885AKT1 4522/4885NR1I2 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.